stockrow
Saturday 7 November 2026
Export DBVT’s income statement to Excel — free account
DBV Technologies S.A.
DBVT Healthcare Biotechnology
DBV Technologies S.A.’s revenue for fiscal 2025 (year ended December 2025) was $5.6 million, up 35.8% from fiscal 2024.
- Revenue
- −42.9%
- EPS
- +40.4%
- Free cash flow
- −64.9%
Quarter to September 2026, against a year earlier
10.57
0.77
+7.86%
Follow DBVT
Alert me
| Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 | Dec '20 | Dec '19 | Dec '18 | Dec '17 | Dec '16 | |
|---|---|---|---|---|---|---|---|---|---|---|
P/E ratio |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Piotroski F-Score |
4 | 2 | 3 | 3 | 2 | 3 | 4 | 3 | 3 | 4 |
P/S ratio |
94.95 | 14.44 | 11.45 | 47.93 | 30.79 | 25.14 | 0.00 | 0.00 | 0.00 | 0.00 |
Altman Z-Score |
1.33 | (10.72) | 0.22 | 0.92 | (1.74) | (3.58) | 0.58 | (0.01) | 10.53 | 20.02 |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Altman Z″-Score (non-manufacturers) |
(2.64) | (24.08) | 0.74 | 3.01 | (4.35) | (8.44) | (7.60) | (3.24) | (0.88) | 7.25 |
Beneish M-Score |
— | — | — | — | — | (3.07) | (2.15) | 6.14 | (3.24) | — |
P/Operating CF |
(15.21) | (4.89) | (13.16) | (9.72) | (9.35) | (8.45) | 0.00 | 0.00 | 0.00 | 0.00 |
P/B ratio |
3.17 | 2.19 | 1.29 | 1.19 | 1.77 | 1.38 | 0.00 | 0.00 | 0.00 | 0.00 |
Price to Tangible BV |
3.17 | 2.19 | 1.29 | 1.19 | 1.77 | 1.38 | 0.00 | 0.00 | 0.00 | 0.00 |
EV/Sales |
60.52 | 6.66 | 2.48 | 4.78 | 17.28 | 7.77 | 0.00 | 0.00 | 0.00 | 0.00 |
EV/EBITDA |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.45 | 0.00 | 0.00 | 0.00 |
EV/Operating CF |
(2.81) | (0.26) | (0.49) | (0.42) | (0.91) | (0.53) | 0.40 | 0.33 | 0.54 | 0.00 |
EV/FCF |
(2.80) | (0.26) | (0.48) | (0.41) | (0.91) | (0.52) | 0.39 | 0.32 | 0.49 | 0.00 |
Quick Ratio |
3.35 | 1.04 | 3.79 | 7.09 | 2.46 | 3.77 | 3.68 | 3.20 | 3.87 | 8.89 |
Current Ratio |
3.67 | 1.43 | 4.26 | 7.56 | 3.64 | 3.93 | 3.79 | 3.34 | 4.37 | 9.38 |
Net Debt/EBITDA |
1.35 | 0.28 | 1.56 | 2.51 | 0.86 | 1.32 | 1.14 | 0.74 | 0.96 | 2.20 |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.20% | 0.30% | 0.74% | 1.03% | 1.41% |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.01 | 0.01 | 0.02 |
Asset Turnover |
0.04 | 0.03 | 0.07 | 0.02 | 0.03 | 0.04 | 0.06 | 0.09 | 0.05 | 0.03 |
Operating CF/Net income |
0.82 | 0.92 | 1.10 | 0.58 | 1.11 | 1.04 | 0.86 | 0.82 | 0.77 | 0.52 |
Capex/Depreciation |
(0.17) | 2.53 | 0.05 | (0.06) | (0.04) | (0.26) | (2.16) | (1.68) | (2.58) | (6.08) |
Interest Coverage |
— | — | — | (223.56) | (196.87) | (219.40) | (452.44) | (473.55) | (43.60) | (7,254.23) |
| (149.83%) | (135.96%) | (43.47%) | (65.55%) | (64.19%) | (80.04%) | (102.26%) | (135.22%) | (80.34%) | (40.47%) | |
| (98.17%) | (91.63%) | (33.87%) | (48.96%) | (46.69%) | (58.66%) | (72.49%) | (97.14%) | (64.32%) | (36.25%) | |
ROIC |
0.00% | 0.00% | 0.00% | 0.00% | (280.50%) | (1,025.38%) | (14,425.02%) | 0.00% | 0.00% | 0.00% |
Return on Tangible Assets |
(88.90%) | (463.87%) | (54.19%) | (46.14%) | (96.71%) | (88.91%) | (97.97%) | (135.97%) | (106.45%) | (44.80%) |
Average Days of Receivables |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 72.18 | 134.36 | 412.18 | 38.77 | 50.23 |
Research and Development Expense of Revenue |
2,070.30% | 2,152.30% | 382.90% | 1,559.52% | 1,232.24% | 901.09% | 782.59% | 737.23% | 883.64% | 867.76% |
Selling, General and Administrative Expense of Revenue |
638.93% | 756.40% | 203.06% | 535.34% | 611.55% | 398.72% | 480.20% | 506.07% | 433.80% | 509.54% |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Share Based Compensation of Revenue |
95.58% | 111.30% | 38.27% | 103.76% | 54.70% | (10.02%) | 117.21% | 178.19% | 258.47% | 378.17% |
Graham Net Nets |
0.28 | 0.10 | 0.64 | 0.74 | 0.38 | 0.50 | 0.00 | 0.00 | 0.00 | 0.00 |
Graham Number |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Earnings Yield |
(27.57%) | (187.13%) | (41.18%) | (43.33%) | (56.25%) | (46.45%) | (10.56%) | (102.85%) | (55.20%) | (22.55%) |
Free Cash Flow Yield |
(22.75%) | (178.22%) | (44.60%) | (24.31%) | (61.78%) | (59.40%) | 0.00% | 0.00% | 0.00% | 0.00% |
Revenue per Share |
0.20 | 0.21 | 0.83 | 0.31 | 0.52 | 1.04 | 1.99 | 2.97 | 2.72 | 2.06 |
Operating CF per Share |
(4.34) | (5.39) | (4.19) | (3.60) | (9.86) | (15.31) | (20.04) | (27.89) | (26.10) | (13.47) |
Capex per Share |
(0.02) | (0.12) | (0.04) | (0.05) | (0.03) | (0.26) | (0.76) | (0.97) | (1.72) | (1.86) |
Free Cash Flow per Share |
(4.36) | (5.51) | (4.22) | (3.64) | (9.88) | (15.56) | (20.80) | (28.86) | (27.82) | (15.33) |
Cash per Share |
6.96 | 1.67 | 7.43 | 13.52 | 7.04 | 18.15 | 26.11 | 25.06 | 31.48 | 58.03 |
Shareholders Equity per Share |
6.05 | 1.41 | 7.37 | 12.56 | 9.04 | 18.99 | 26.10 | 24.76 | 29.66 | 54.95 |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Book value per Share |
6.05 | 1.41 | 7.37 | 12.56 | 9.04 | 18.99 | 26.10 | 24.76 | 29.66 | 54.95 |
Free Cash Flow |
(121.72) | (106.81) | (80.33) | (56.41) | (108.56) | (168.37) | (153.94) | (166.96) | (137.74) | (74.97) |
Working Capital |
154.92 | 13.25 | 121.58 | 193.55 | 82.99 | 154.66 | 150.55 | 120.37 | 136.69 | 269.10 |
Capital Expenditures |
(0.54) | (2.34) | (0.68) | (0.75) | (0.31) | (2.76) | (5.60) | (5.61) | (8.53) | (9.08) |
Net Current Asset Value |
148.00 | 6.12 | 116.12 | 171.01 | 66.94 | 140.62 | 126.01 | 112.20 | 123.18 | 251.78 |
EV/EBIT |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Capex to Sales |
0.10 | 0.56 | 0.04 | 0.15 | 0.06 | 0.24 | 0.38 | 0.33 | 0.63 | 0.90 |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Other line items | ||||||||||
Depreciation/Fixed assets |
0.31 | (0.08) | (1.11) | 0.87 | 0.46 | 0.42 | 0.10 | 0.14 | 0.16 | 0.11 |
Cash ROIC |
(33.54%) | (178.49%) | (28.53%) | (13.98%) | (61.48%) | (41.84%) | (39.75%) | (57.62%) | (45.20%) | (13.46%) |
Accounts Receivable Turnover |
0.00 | 0.00 | 0.00 | 0.22 | 0.32 | 2.95 | 1.19 | 1.65 | 9.57 | 12.86 |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Inventory Turnover |
— | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Days of Inventory on Hand |
— | — | — | 0.00 | 0.00 | 48.27 | 0.00 | 0.00 | 0.00 | 0.00 |
Average Receivables |
— | — | — | 22.10 | 17.64 | 3.82 | 12.40 | 10.41 | 1.41 | 0.78 |
Average Payables |
31.49 | 22.67 | 18.89 | 12.95 | 15.88 | 22.17 | 28.87 | 26.44 | 17.17 | 13.16 |
Average Inventory |
— | — | — | — | — | 2.40 | 2.07 | 1.00 | — | — |
Average Assets |
149.69 | 124.32 | 214.75 | 196.62 | 209.48 | 271.99 | 237.28 | 201.91 | 259.56 | 349.67 |
Average Common Equity |
98.08 | 83.79 | 167.32 | 146.86 | 152.38 | 199.34 | 168.21 | 145.05 | 207.79 | 313.19 |
Columns are period end dates · fundamentals updated 2 Nov 2026